Nuvectis to Present NXP900 Synergy and Resistance Data at AACR April 21–22
Nuvectis Pharma will present Phase 1b data for NXP900, a YES1/SRC inhibitor, demonstrating synergy with KRAS inhibitors and IL13RA2-AKT-mediated resistance reversal in NSCLC and cholangiocarcinoma at the AACR meeting April 21–22. Additional April 21 poster details NXP900’s targeting of myeloid-derived suppressor cells to restore antitumor immunity in NSCLC.
1. Presentation Schedule
Nuvectis Pharma will present three posters on NXP900 at the AACR meeting in San Diego, with two sessions on April 21 (combination targeted therapy and MDSC targeting) and one on April 22 (novel resistance reversal strategies).
2. Synergy and Resistance Findings
A Phase 1b poster will detail NXP900’s potent synergy with KRAS inhibitors in NSCLC models and another will explain how IL13RA2-AKT signaling drives resistance in cholangiocarcinoma and how combination therapy can overcome it.
3. Immunomodulatory Strategy
The April 21 Tyrosine Kinase session will cover NXP900’s inhibition of SRC family kinases to target myeloid-derived suppressor cells, aiming to restore antitumor immune responses in NSCLC models.
4. Drug Profile and Development
NXP900 is an oral small molecule SRC Family of Kinases inhibitor that has completed Phase 1a dose escalation and drug-drug interaction studies and is now advancing its Phase 1b program exploring combination approaches in oncology.